Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Current Deferred Revenue (2024)

Perspective Therapeutics (CATX) has disclosed Current Deferred Revenue for 1 consecutive years, with $1.4 million as the latest value for Q4 2024.

  • Quarterly Current Deferred Revenue changed N/A to $1.4 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2024, changed N/A year-over-year, with the annual reading at $1.4 million for FY2024, N/A changed from the prior year.
  • Current Deferred Revenue hit $1.4 million in Q4 2024 for Perspective Therapeutics, roughly flat from $1.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.4 million in Q1 2024 to a low of $1.4 million in Q1 2024.